Consistently, reports from an international registry showed that administration of TNF antagonists to IBD patients was not associated with severe SARS-CoV-2 outcomes, such as admission to an ICU, ventilator use, hospitalization, or death [7, 82, 89]. Here, TNF is linked to inflammatory bowel disease.